E-LIB Suche - Ergebnisse für: Wu, Yilong

1

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSC..:

Zhang, Chao ; Sun, Yu-Xuan ; Yi, Ding-Cheng...
Cell Reports Medicine. 5 (2024) 7 - p. 101615 , 2024

Link: https://doi.org/10.1016/..

2

Redoxhighphenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mut..:

Wei, Xue-Wu ; Lu, Chang ; Zhang, Yi-Chen...
OncoImmunology. 13 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

3

Summary of Research: Overall Survival with Osimertinib in R..:

Tsuboi, Masahiro ; Herbst, Roy S. ; John, Thomas...
Targeted Oncology. 19 (2024) 2 - p. 131-134 , 2024

Link: https://doi.org/10.1007/..

4

Molecular features and clinical outcomes of EGFR-mutated, M..:

Fang, Mei-Mei ; Cheng, Jiang-Tao ; Chen, Yu-Qing...
Therapeutic Advances in Medical Oncology. 16 (2024) - p. , 2024

Link: https://doi.org/10.1177/..

5

Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monothera..:

Zhou, Qing ; Meng, Xiangjiao ; Sun, Longhua...
Journal of Thoracic Oncology. , 2024

Link: https://doi.org/10.1016/..

6

PP01.104 Vebreltinib Efficacy In METex14 Mutant NSCLC With ..:

Awad, Mark M. ; Devarakonda, Siddhartha ; Yang, Jin-Li...
Journal of Thoracic Oncology. 19 (2024) 7 - p. e45-e46 , 2024

Link: https://doi.org/10.1016/..

7

Evaluation of molecular residual disease in operable non-sm..:

Fu, Rui ; Xiong, Yuanyuan ; Cai, Miao...
Frontiers of Medicine. 18 (2024) 4 - p. 735-743 , 2024

Link: https://doi.org/10.1007/..

8

Tumor immune microenvironment of NSCLC with EGFR exon 20 in..:

Liu, Ke-Jun ; Li, Hong-Rui ; Tan, Quan-Quan...
Lung Cancer. 195 (2024) - p. 107933 , 2024

Link: https://doi.org/10.1016/..

9

A novel small‐animal locomotor activity recording device fo..:

Wu, Yi‐Long ; Zhong, Ming ; Yin, Jun...
Animal Models and Experimental Medicine. 7 (2024) 1 - p. 71-76 , 2024

Link: https://doi.org/10.1002/..

10

Study of Magnetic Coupler With Clutch for Superconducting F..:

Wu, Yilong ; Zhang, Guomin ; Wu, Yue..
IEEE Transactions on Applied Superconductivity. 34 (2024) 5 - p. 1-5 , 2024

Link: https://doi.org/10.1109/..

11

Tepotinib plus osimertinib in patients with EGFR-mutated no..:

Wu, Yi-Long ; Guarneri, Valentina ; Voon, Pei Jye...
The Lancet Oncology. 25 (2024) 8 - p. 989-1002 , 2024

Link: https://doi.org/10.1016/..

12

Correlation of distribution characteristics and dynamic cha..:

Luo, Wei-Chi ; Mei, Shi-Qi ; Huang, Zi-Jian...
Journal of Translational Medicine. 22 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

13

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR..:

Wang, Jie ; Wu, Yi-Long ; Lu, Shun...
JTO Clinical and Research Reports. 5 (2024) 2 - p. 100621 , 2024

Link: https://doi.org/10.1016/..

14

Combination of Cytologic Findings and Circulating Tumor DNA..:

Lin, Jia-Xin ; Yin, Kai ; Yan, Li-Xu...
JTO Clinical and Research Reports. 5 (2024) 9 - p. 100704 , 2024

Link: https://doi.org/10.1016/..

15

Neoadjuvant SHR-1701 with or without chemotherapy in unrese..:

Zhou, Qing ; Pan, Yi ; Yang, Xuening...
Cancer Cell. 42 (2024) 7 - p. 1258-1267.e2 , 2024

Link: https://doi.org/10.1016/..